Human Liver Dendritic Cells Promote T Cell Hyporesponsiveness
Overview
Authors
Affiliations
The liver is believed to promote tolerance, which may be beneficial due to its constant exposure to foreign Ags from the portal circulation. Although dendritic cells (DCs) are critical mediators of immune responses, little is known about human liver DCs. We compared freshly purified liver DCs from surgical specimens with autologous blood DCs. Liver and blood DCs were equally immature, but had distinct subset compositions. BDCA-1(+) DCs represented the most prevalent liver DC subset, whereas the majority of peripheral blood DCs were CD16(+). Upon TLR4 ligation, blood DCs secreted multiple proinflammatory cytokines, whereas liver DCs produced substantial amounts of IL-10. Liver DCs induced less proliferation of allogeneic T cells both in a primary MLR and after restimulation. Similarly, Ag-specific CD4(+) T cells were less responsive to restimulation when initially stimulated by autologous liver DCs rather than blood DCs. In addition, liver DCs generated more suppressive CD4(+)CD25(+)FoxP3(+) T regulatory cells and IL-4-producing Th2 cells via an IL-10-dependent mechanism. Our findings are critical to understanding hepatic immunity and demonstrate that human liver DCs promote immunologic hyporesponsiveness that may contribute to hepatic tolerance.
Research Progress on the Immune Function of Liver Sinusoidal Endothelial Cells in Sepsis.
Wang X, Guo Z, Xia Y, Wang X, Wang Z Cells. 2025; 14(5).
PMID: 40072101 PMC: 11899273. DOI: 10.3390/cells14050373.
Abdallah M, Voland R, Decamp M, Flickinger J, Pacioles T, Jamil M Cancers (Basel). 2025; 16(24.
PMID: 39766108 PMC: 11674749. DOI: 10.3390/cancers16244207.
Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.
Liu H, Lu Y, Zong J, Zhang B, Li X, Qi H J Nanobiotechnology. 2024; 22(1):663.
PMID: 39465376 PMC: 11520105. DOI: 10.1186/s12951-024-02913-7.
The renaissance of oral tolerance: merging tradition and new insights.
Cerovic V, Pabst O, Mowat A Nat Rev Immunol. 2024; 25(1):42-56.
PMID: 39242920 DOI: 10.1038/s41577-024-01077-7.
Locoregional therapies combined with immune checkpoint inhibitors for liver metastases.
Zhang X, Zhou Y, Wei G, Luo Y, Qiu M Cancer Cell Int. 2024; 24(1):302.
PMID: 39217341 PMC: 11365172. DOI: 10.1186/s12935-024-03484-1.